Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer

Sang Yeon Suh, Youn Seon Choi, Chang Hwan Yeom, Sang Mi Kwak, Ho Min Yoon, Dae Gyun Kim, Su Jin Koh, Jeanno Park, Myung Ah Lee, Yong Joo Lee, Ah Ram Seo, Hong Yup Ahn, Eunji Yim

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer. Methods: In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancer patients until death or the end of the study. Approximately 60 % of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model. Results: The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival. Conclusions: IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study.

Original languageEnglish
Pages (from-to)3071-3077
Number of pages7
JournalSupportive Care in Cancer
Volume21
Issue number11
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Interleukin-6
Tumor Necrosis Factor-alpha
Survival
Neoplasms
Hospice Care
Republic of Korea
Cachexia
Anorexia
Palliative Care
Proportional Hazards Models
Cohort Studies
Multivariate Analysis
Prospective Studies
Cytokines
Infection

Keywords

  • Advanced cancer
  • Interleukin-6
  • Survival
  • Tumour necrosis factor-alpha

ASJC Scopus subject areas

  • Oncology

Cite this

Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. / Suh, Sang Yeon; Choi, Youn Seon; Yeom, Chang Hwan; Kwak, Sang Mi; Yoon, Ho Min; Kim, Dae Gyun; Koh, Su Jin; Park, Jeanno; Lee, Myung Ah; Lee, Yong Joo; Seo, Ah Ram; Ahn, Hong Yup; Yim, Eunji.

In: Supportive Care in Cancer, Vol. 21, No. 11, 01.11.2013, p. 3071-3077.

Research output: Contribution to journalArticle

Suh, SY, Choi, YS, Yeom, CH, Kwak, SM, Yoon, HM, Kim, DG, Koh, SJ, Park, J, Lee, MA, Lee, YJ, Seo, AR, Ahn, HY & Yim, E 2013, 'Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer', Supportive Care in Cancer, vol. 21, no. 11, pp. 3071-3077. https://doi.org/10.1007/s00520-013-1878-4
Suh, Sang Yeon ; Choi, Youn Seon ; Yeom, Chang Hwan ; Kwak, Sang Mi ; Yoon, Ho Min ; Kim, Dae Gyun ; Koh, Su Jin ; Park, Jeanno ; Lee, Myung Ah ; Lee, Yong Joo ; Seo, Ah Ram ; Ahn, Hong Yup ; Yim, Eunji. / Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. In: Supportive Care in Cancer. 2013 ; Vol. 21, No. 11. pp. 3071-3077.
@article{59c3a40e19a744208856a978febf8a04,
title = "Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer",
abstract = "Purpose: The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer. Methods: In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancer patients until death or the end of the study. Approximately 60 {\%} of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model. Results: The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival. Conclusions: IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study.",
keywords = "Advanced cancer, Interleukin-6, Survival, Tumour necrosis factor-alpha",
author = "Suh, {Sang Yeon} and Choi, {Youn Seon} and Yeom, {Chang Hwan} and Kwak, {Sang Mi} and Yoon, {Ho Min} and Kim, {Dae Gyun} and Koh, {Su Jin} and Jeanno Park and Lee, {Myung Ah} and Lee, {Yong Joo} and Seo, {Ah Ram} and Ahn, {Hong Yup} and Eunji Yim",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/s00520-013-1878-4",
language = "English",
volume = "21",
pages = "3071--3077",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer

AU - Suh, Sang Yeon

AU - Choi, Youn Seon

AU - Yeom, Chang Hwan

AU - Kwak, Sang Mi

AU - Yoon, Ho Min

AU - Kim, Dae Gyun

AU - Koh, Su Jin

AU - Park, Jeanno

AU - Lee, Myung Ah

AU - Lee, Yong Joo

AU - Seo, Ah Ram

AU - Ahn, Hong Yup

AU - Yim, Eunji

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Purpose: The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer. Methods: In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancer patients until death or the end of the study. Approximately 60 % of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model. Results: The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival. Conclusions: IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study.

AB - Purpose: The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer. Methods: In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancer patients until death or the end of the study. Approximately 60 % of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model. Results: The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival. Conclusions: IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study.

KW - Advanced cancer

KW - Interleukin-6

KW - Survival

KW - Tumour necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=84885572117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885572117&partnerID=8YFLogxK

U2 - 10.1007/s00520-013-1878-4

DO - 10.1007/s00520-013-1878-4

M3 - Article

C2 - 23828393

AN - SCOPUS:84885572117

VL - 21

SP - 3071

EP - 3077

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -